Clinical trials: sponsored by Zhejiang Cancer Hospital
Breast Cancer
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
By measuring the intestinal flora abundance and bacterial count of patients in the early stage of using pyrotinib to clarify the relationship between diarrhea caused by pyrotinib and changes in intestinal flora in breast cancer…
- Trial name
- NCT05030519
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Brachytherapy, Uterine Cervical Neoplasms
Retrospective Study of Brachytherapy
Brachytherapy for gynecological cancers will be studied retrospectively.
- Conditions
- Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer
- Trial name
- RetroBT (NCT05242861)
- Testing
- Brachytherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM
- Trial name
- NCT05232552
- Testing
- Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Uterine Cervical Neoplasms, Oncolytic Virotherapy
H101 Combined With Camrelizumab for Recurrent Cervical Cancer
There is no standard treatment for recurrent cervical cancer that progresses or persists after first-line treatment. The objective response rate of anti-PD-1 antibody treatment is about 15%.
- Conditions
- Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab
- Trial name
- NCT05234905
- Testing
- Recombinant human adenovirus type 5＋Camrelizumab
- Where
- 4 sites in China
- Volunteers
- 55 people
- Sponsor
- Zhejiang Cancer Hospital
Cervical Cancer
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur.
- Trial name
- PAILACC (NCT04974346)
- Testing
- Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation, Pelvic definitive concurrent chemoradiation
- Where
- 7 sites in China
- Volunteers
- 455 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
A multi-center, open, randomized controlled, phase II clinical study to evaluate the efficiency and safety of chemotherapy and immunotherapy combined with locol radiotharepy in treatment of patients with oligometastatic…
- Trial name
- NCT05183958
- Testing
- Radiotherapy group, Camrelizumab, Chemotherapy
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Zhejiang Cancer Hospital
Mismatch Repair-proficient, Colorectal Cancer Metastatic
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and tolerability of radiotherapy combined with…
- Conditions
- Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable
- Trial name
- NCT05160727
- Testing
- Tislelizumab, Irinotecan, radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04506138
- Testing
- Camrelizumab, Paclitaxel for Injection (Albumin Bound), Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer Stage III
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.
- Trial name
- NCT05148767
- Testing
- Neoadjuvant chemoradiotherapy based on irinotecan
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Breast Cancer
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC
To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
- Trial name
- NCT05131841
- Testing
- Cipterbin Combined With Vinorelbine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis.
- Trial name
- NCT05126160
- Testing
- Immune Score Based Radiomics
- Where
- 5 sites in China
- Volunteers
- 494 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Rectal Cancer
Dendrobium Huoshanense Suppository in Rectal Cancer
To evaluates the role of Dendrobium Huoshanense Suppository for radiation proctitis in locally advanced rectal cancer treated by capecitabine and irinotecan based neoadjuvant chemoradiation.
- Trial name
- NCT05079438
- Testing
- Dendrobium Huoshanense Suppository
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Neoplasm Female
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine monotherapy or combination regimens, both with benefit diminishing as resistance develops.
- Trial name
- NCT05075512
- Testing
- anlotinib, fulvestrant
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, PI3K/AKT/mTOR Pathway Mutation
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic breast cancer patients with PI3K/AKT/mTOR…
- Conditions
- Breast Cancer, PI3K/AKT/mTOR Pathway Mutation, Everolimus
- Trial name
- NCT05054166
- Testing
- No intervention, it was a retrospective study.
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
In this study, patients with hepatocellular carcinoma were used as the research object to explore the effectiveness and safety of idarubicin hepatic artery perfusion combined with lipiodol embolization, and to preliminarily…
- Trial name
- NCT05053386
- Testing
- Idarubicin Hydrochloride for Injection, Epirubicin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC Stage IV, Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
- Conditions
- NSCLC Stage IV, Brain Metastases, Immunotherapy
- Trial name
- NCT04291092
- Testing
- Immunotherapy, WBRT, Chemotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma Stage IIIa
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Lenvatinib Plus Hepatic Arterial Infusion of Modified FOLFOX Regime vs Lenvatinib Plus Hepatic Arterial Infusion of Oxaliplatin Plus Raltitrexed in Patients with Advanced Hepatocellular Carcinoma
- Trial name
- NCT05007587
- Testing
- Lenvatinib, mFOLFOX regimen, ROX regimen
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Recurrence
RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer
This study will conduct a multicenter, open, prospective clinical trial to observe the RecurIndex to assist in predicting the risk of recurrence in patients with early-stage Luminal-type breast cancer.
- Trial name
- NCT04972448
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Neoplasms
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
The international treatment guidelines now include recommendations for the use of CDK 4/6 inhibitors in combination with hormone agents for the treatment of postmenopausal women with hormone-receptor-positive/HER2-negative ABC as…
- Trial name
- NCT04858997
- Testing
- Palbociclib, AI
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital